A selective IDO1 inhibitor, KHK2455, improves efficacy of PD-L1 blockade by modulating both innate and adaptive immunity in a mouse melanoma model
Masato Saito, Kana Kunieda, Toshihiko Ishii, Shoko Koshiba, Rui Ohashi, Yutaka Kanda, Takuji Yamada · 2025
Read A selective IDO1 inhibitor, KHK2455, improves efficacy of PD-L1 blockade by modulating both innate and adaptive immunity in a mouse melanoma model by Masato Saito, Kana Kunieda, Toshihiko Ishii, Shoko Koshiba, Rui Ohashi, Yutaka Kanda, Takuji Yamada (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717313.txt.
Description
Masato Saito and six co-authors report a lab study, published in twenty twenty-five, on a drug called KHK2455 in mice with skin tumors. The drug blocks an enzyme that helps tumors grow by breaking down a key amino acid. Alone, the drug lowered the waste product of that process but did not shrink the tumors.
Paired with a second treatment that blocks a brake on immune cells, the drug worked much better than that treatment alone. The two treatments acted on different arms of the immune system. One woke up helper T cells, while the other raised the number of killer cells and other first-line defenders. Together they turned on both arms at once, a result that may guide future paired treatment plans.
Catalog record
| CREATOR | Masato Saito, Kana Kunieda, Toshihiko Ishii, Shoko Koshiba, Rui Ohashi, Yutaka Kanda, Takuji Yamada |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |